Pozen appoints Dr Tomas Bocanegra head of development
This article was originally published in Scrip
Executive Summary
Pozen has appointed Dr Tomas Bocanegra executive vice-president of development, responsible for driving all product development activities beginning with the company's lead pipeline candidate, PA32540 (aspirin and omeprazole), for myocardial infarction. Prior to joining Pozen, Dr Bocanegra served as senior vice-president of development at Daiichi Sankyo Pharma Development.